Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan

Journal of Immunology

Volumn 183, Issue 2, 2009, Pages 1393-1402

  Abu Taha, May ^a   Rius, Cristina ^a   Hermenegildo, Carlos ^b   Noguera, Inmaculada ^b   Cerda Nicolas, Jose Miguel ^b,d   Issekutz, Andrew C ^e   Jose, Peter J ^a   Cortijo, Julio ^a,c,d   Morcillo, Esteban J ^a,b,d   Sanz, Maria Jesus ^a,d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CD11B ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; ESTRADIOL; INTERLEUKIN 8; LOSARTAN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; CHEMOKINE; ESTROGEN;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTERY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM; FEMALE; HORMONE SUBSTITUTION; HUMAN; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; LONG TERM CARE; LOW DRUG DOSE; MALE; MICROSCOPY; MONOCYTE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; VEIN; ANIMAL; BLOOD; CASE CONTROL STUDY; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; MENOPAUSE; MIDDLE AGED; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZAZEPINES; CASE-CONTROL STUDIES; CELL ADHESION; CELL ADHESION MOLECULES; CELLS, CULTURED; CHEMOKINES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES; LOSARTAN; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70249116821     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803157     Document Type: Article

References (47)

1. Wenger, N. K., L. Speroff, and B. Packard. 1993. Cardiovascular health and disease in women. N. Engl. J. Med. 329: 247-256.
2. Godsland, I. F., V. Wynn, D. Crook, and N. E. Miller. 1987. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am. Heart J. 114: 1467-1503.
3. Grodstein, F., M. J. Stampfer, G. A. Colditz, W. C. Willett, J. E. Manson, M. Joffe, B. Rosner, C. Fuchs, S. E. Hankinson, D. J. Hunter, et al. 1997. Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 336: 1769-1775.
4. Selzman, C. H., T. A. Whitehill, B. D. Shames, E. J. Pulido, B. S. Cain, and A. H. Harken. 1998. The biology of estrogen-mediated repair of cardiovascular injury. Ann. Thorac. Surg. 65: 868-874.
5. Stork, S., C. von Schacky, and P. Angerer. 2002. The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 165: 301-307.
6. Stork, S., Y. T. van der Schouw, D. E. Grobbee, and M. L. Bots. 2004. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol. Metab. 15: 66-72.
7. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288: 321-333.
8. Dzau, V. J. 2001. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37: 1047-1052.
9. Schunkert, H., A. H. Danser, H. W. Hense, F. H. Derkx, S. Kurzinger, and G. A. Riegger. 1997. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 95: 39-45.
10. Wassmann, S., and G. Nickenig. 2006. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J. Hypertens. 24(Suppl.): S15-S21.
11. Klett, C., D. Ganten, W. Hellmann, M. Kaling, G. U. Ryffel, T. Weimar-Ehl, and E. Hackenthal. 1992. Regulation of hepatic angiotensinogen synthesis and secretion by steroid hormones. Endocrinology 130: 3660-3668.
12. Harvey, P. J., L. M. Wing, J. Savage, and D. Molloy. 1999. The effects of different types and doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women. J. Hypertens. 17: 405-411.
13. Warnholtz, A., G. Nickenig, E. Schulz, R. Macharzina, J. H. Brasen, M. Skatchkov, T. Heitzer, J. P. Stasch, K. K. Griendling, D. G. Harrison, et al. 1999. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99: 2027-2033.
14. Alvarez, A., C. Hermenegildo, A. C. Issekutz, J. V. Esplugues, and M. J. Sanz. 2002. Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ. Res. 91: 1142-1150.
15. Alvarez, A., M. Cerda-Nicolas, Y. Naim Abu Nabah, M. Mata, A. C. Issekutz, J. Panes, R. R. Lobb, and M. J. Sanz. 2004. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104: 402-408. (Pubitemid 38900021)
16. Li, H., M. I. Cybulsky, M. A. Gimbrone, Jr., and P. Libby. 1993. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 13: 197-204.
17. Shin, W. S., A. Szuba, and S. G. Rockson. 2002. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160: 91-102.
18. Price, D. T., and J. Loscalzo. 1999. Cellular adhesion molecules and atherogenesis. Am. J. Med. 107: 85-97.
19. Reape, T. J., and P. H. Groot. 1999. Chemokines and atherosclerosis. Atherosclerosis 147: 213-225.
20. Weber, C., A. Schober, and A. Zernecke. 2004. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler. Thromb. Vasc. Biol. 24: 1997-2008.
21. Mateo, T., Y. N. Abu Nabah, M. Abu Taha, M. Mata, M. Cerda-Nicolas, A. E. Proudfoot, R. A. Stahl, A. C. Issekutz, J. Cortijo, E. J. Morcillo, et al. 2006. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J. Immunol. 176: 5577-5586.
22. Genant, H. K., J. Lucas, S. Weiss, M. Akin, R. Emkey, H. McNaney-Flint, R. Downs, J. Mortola, N. Watts, H. M. Yang, et al. 1997. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels: Estratab/Osteoporosis Study Group. Arch. Intern. Med. 157: 2609-2615.
23. House, S. D., and H. H. Lipowsky. 1987. Leukocyte-endothelium adhesion: microhemodynamics in mesentery of the cat. Microvasc. Res. 34: 363-379.
24. Landmesser, U., B. Hornig, and H. Drexler. 2004. Endothelial function: a critical determinant in atherosclerosis? Circulation 109(Suppl. 1): II27-II33.
25. Koh, K. K., J. W. Son, J. Y. Ahn, S. K. Lee, H. Y. Hwang, D. S. Kim, D. K. Jin, T. H. Ahn, and E. K. Shin. 2001. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int. J. Cardiol. 81: 43-50.
26. Miller, A. P., Y. F. Chen, D. Xing, W. Feng, and S. Oparil. 2003. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 42: 657-663.
27. Huang, S., J. D. Paulauskis, and L. Kobzik. 1992. Rat KC cDNA cloning and mRNA expression in lung macrophages and fibroblasts. Biochem. Biophys. Res. Commun. 184: 922-929.
28. Huo, Y., C. Weber, S. B. Forlow, M. Sperandio, J. Thatte, M. Mack, S. Jung, D. R. Littman, and K. Ley. 2001. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J. Clin. Invest. 108: 1307-1314.
29. Kraaijeveld, A. O., S. C. de Jager, W. J. de Jager, B. J. Prakken, S. R. McColl, I. Haspels, H. Putter, T. J. van Berkel, L. Nagelkerken, J. W. Jukema, and E. A. Biessen. 2007. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 116: 1931-1941.
30. Terao, S., G. Yilmaz, K. Y. Stokes, J. Russell, M. Ishikawa, T. Kawase, and D. N. Granger. 2008. Blood cell-derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia-reperfusion. Stroke 39: 2560-2570.
31. Kameyoshi, Y., A. Dorschner, A. I. Mallet, E. Christophers, and J. M. Schroder. 1992. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J. Exp. Med. 176: 587-592.
32. Kameyoshi, Y., J. M. Schroder, E. Christophers, and S. Yamamoto. 1994. Identification of the cytokine RANTES released from platelets as an eosinophil chemotactic factor. Int. Arch. Allergy Immunol. 104(Suppl. 1): 49-51. (Pubitemid 24124632)
33. von Hundelshausen, P., K. S. Weber, Y. Huo, A. E. Proudfoot, P. J. Nelson, K. Ley, and C. Weber. 2001. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777.
34. Brosnihan, K. B., D. Weddle, M. S. Anthony, C. Heise, P. Li, and C. M. Ferrario. 1997. Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J. Hypertens. 15: 719-726.
35. Nickenig, G., A. T. Baumer, C. Grohe, S. Kahlert, K. Strehlow, S. Rosenkranz, A. Stablein, F. Beckers, J. F. Smits, M. J. Daemen, et al. 1998. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97: 2197-2201.
36. Brown, N. J., A. Abbas, D. Byrne, J. A. Schoenhard, and D. E. Vaughan. 2002. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 105: 304-309.
37. Ichikawa, J., H. Sumino, S. Ichikawa, and M. Ozaki. 2006. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am. J. Hypertens. 19: 744-749.
38. Petnehazy, T., K. Y. Stokes, J. M. Russell, and D. N. Granger. 2005. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension 45: 209-215.
39. Petnehazy, T., K. Y. Stokes, K. C. Wood, J. Russell, and D. N. Granger. 2006. Role of blood cell-associated AT1 receptors in the microvascular responses to hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26: 313-318.
40. Lambrinoudaki, I., G. Christodoulakos, D. Rizos, E. Economou, J. Argeitis, S. Vlachou, M. Creatsa, E. Kouskouni, and D. Botsis. 2006. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur. J. Endocrinol. 154: 907-916. (Pubitemid 43997731)
41. Shakir, Y. A., G. Samsioe, P. Nyberg, J. Lidfeldt, and C. Nerbrand. 2006. Does the hormonal situation modify lipid effects by lifestyle factors in middle-aged women?: results from a population-based study of Swedish women: the women's health in the Lund area study. Metabolism 55: 1060-1066.
42. Higashi, Y., M. Sanada, S. Sasaki, K. Nakagawa, C. Goto, H. Matsuura, K. Ohama, K. Chayama, and T. Oshima. 2001. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 37: 651-657.
43. Sanada, M., Y. Higashi, K. Nakagawa, S. Sasaki, I. Kodama, T. Sakashita, M. Tsuda, and K. Ohama. 2001. Estrogen replacement therapy in postmenopausal women augments reactive hyperemia in the forearm by reducing angiotensin converting enzyme activity. Atherosclerosis 158: 391-397. (Pubitemid 32913649)
44. Gerhard, M., B. W. Walsh, A. Tawakol, E. A. Haley, S. J. Creager, E. W. Seely, P. Ganz, and M. A. Creager. 1998. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98: 1158-1163.
45. Wei, C. C., Q. C. Meng, R. Palmer, G. R. Hageman, J. Durand, W. E. Bradley, D. M. Farrell, G. H. Hankes, S. Oparil, and L. J. Dell'Italia. 1999. Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99: 2583-2589.
46. Mervaala, E. M., D. N. Muller, J. K. Park, F. Schmidt, M. Lohn, V. Breu, D. Dragun, D. Ganten, H. Haller, and F. C. Luft. 1999. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33: 389-395.
47. Silva-Antonialli, M. M., R. C. Tostes, L. Fernandes, D. R. Fior-Chadi, E. H. Akamine, M. H. Carvalho, Z. B. Fortes, and D. Nigro. 2004. A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc. Res. 62: 587-593.